United StatesÚltimas notícias

Chimeric Therapeutics (ASX:CHM) has secured $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 clinical trial through the end of Phase 1.

Venezuela is reportedly settling close to 80% of its crude oil export revenues using cryptocurrencies, primarily the USDT stablecoin, as traditional payment channels remain constrained by international sanctions.

Digital asset investment products posted their first weekly outflows in four weeks, shedding a combined $952 million.

Cryptocurrency mining has emerged as one of several factors underpinning the recent strength of the Russian ruble, according to comments from the country’s central bank leadership.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have secured their tenth Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration for ENHERTU, marking a pivotal expansion into the early-stage treatment of breast cancer.

Bitcoin (CRYPTO:BTC) is trading close to the $90,000 resistance level on Monday, fuelling cautious optimism of a short-term recovery after recent price weakness.

Bumble (NASDAQ:BMBL) shares surged 4.1% during the morning session, driven by signs of a potential short squeeze, as the stock rallied amid a broader tech stock rebound.

Dominion Energy (NYSE:D) issued a statement today in response to the U.S. Department of Interior’s Director’s Order, which calls for a 90-day suspension of work on the Coastal Virginia Offshore Wind (CVOW) project.

Indivior (NASDAQ:INDV) has announced its inclusion in the S&P SmallCap 600 index, effective December 22, 2025.

The company stated that this milestone aligns its capital markets presence with a sharpened U.S. business profile and supports the growth of SUBLOCADE, its first-in-class long-acting injectable for moderate to severe opioid use disorder.

Zeekr Group (NYSE:ZK) has announced the completion of its merger with Keystone Mergersub, an indirect wholly-owned subsidiary of Geely, effective December 22, 2025.

Janus Henderson Group (NYSE:JHG) has entered into a definitive agreement to be acquired by Nelson Peltz’s Trian Fund Management and venture capital firm General Catalyst in an all-cash transaction valued at approximately $7.4 billion.

NeuroSense Therapeutics (NASDAQ:NRSN) reported on Monday the successful completion of a safety analysis for its Phase 2 NST-AD-001 study, a critical step in the company's efforts to repurpose its lead ALS candidate, PrimeC, for the treatment of Alzheimer’s disease.